Investigational drug · Phase 3
Saruparib
Also called: AZD5305
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, Ovarian Cancer, Endometrial Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
15
Any phase or sponsor naming "Saruparib"
First trial start
2020
Nov 12, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Saruparib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
- Ovarian Cancer
- Endometrial Cancer
- Breast Cancer
- Biliary Tract Carcinoma
- Squamous Non-Small Cell Lung Cancer
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Lung Adenocarcinoma
- Lung Squamous Cell Carcinoma
- Solid Tumours
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Ovarian cancer · Endometrial cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Saruparib" as an intervention, largest first.
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06120491 · 1,898 participants · Start Nov 21, 2023 · Primary completion Sep 30, 2027
Drug: Saruparib; Placebo and 3 more · For: Metastatic Castration-Sensitive Prostate Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 322 sites in all
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07711002 · 1,330 participants (planned) · Start Sep 15, 2026 · Primary completion May 30, 2031
Drug: Saruparib; Enzalutamide and 2 more · For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Hot Springs, Arkansas; Springdale, Arkansas; Beverly Hills, California · 210 sites in all
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT06769126 · 900 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 31, 2028
Drug: Ceralasertib; Durvalumab and 4 more · For: Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype and 2 more
Sites: Loma Linda, California; Rancho Mirage, California; Sacramento, California · 148 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06380751 · 788 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 18, 2029
Drug: Saruparib (AZD5305); Camizestrant and 7 more · For: Advanced Breast Cancer
Sites: Gilbert, Arizona; Fountain Valley, California; Glendale, California · 306 sites in all
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06952803 · 700 participants (planned) · Start Aug 6, 2025 · Primary completion Mar 31, 2033
Drug: Saruparib; Placebo and 2 more · For: Prostate Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; La Jolla, California · 346 sites in all
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05797168 · 622 participants (planned) · Start Jun 5, 2023 · Primary completion Aug 4, 2028
Drug: Torvutatug samrotecan; Saruparib and 4 more · For: Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer and 1 more
Sites: Duarte, California; Irvine, California; La Jolla, California · 60 sites in all
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05123482 · 460 participants (planned) · Start Oct 18, 2021 · Primary completion Sep 29, 2027
Drug: AZD8205; AZD8205 and AZD2936 (Rilvegostomig) and 4 more · For: Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer and 2 more
Sites: Duarte, California; Irvine, California; Santa Monica, California · 67 sites in all
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07446855 · 180 participants (planned) · Start Mar 17, 2026 · Primary completion Mar 29, 2030
Drug: AZD4956; Saruparib · For: Solid Tumours
Sites: New York, New York; Providence, Rhode Island; Houston, Texas · 19 sites in all
- Saruparib in HRDsig+ Solid TumorsNot yet recruiting
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT07832630 · 124 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 1, 2029
Drug: Saruparib · For: Malignant Neoplastic Disease (Disorder)
Sites: Philadelphia, Pennsylvania
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05938270 · 113 participants · Start Sep 21, 2023 · Primary completion Jun 15, 2026
Drug: Saruparib (AZD5305); Darolutamide · For: Prostate Cancer
Sites: Detroit, Michigan; Providence, Rhode Island; Melbourne, Australia · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors.
Ladduwahetty T, Rahemtulla BF, Talbot EPA, et al. · J Med Chem 2026
- PARP inhibitors in metastatic prostate cancer: current evidence and future directions.
McKendry K, Maurice-Dror C, Chi KN · Clin Adv Hematol Oncol 2026
- Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos.
Zhou Z, Yu R, Zhou X, et al. · Adv Sci (Weinh) 2026
- PARP-1 selective inhibitors: A new direction in drug discovery to improve the therapeutic index of PARP-targeted cancer therapy.
Elkafoury EM, El-Moselhy TF, El-Hamamsy MH, et al. · Drug Discov Today 2026
- [18F]Pamiparib: Synthesis and evaluation of a novel PARP1/2 radiotracer in rodent and nonhuman primate brain.
Tong J, Hernandez-Martin N, Balayeva T, et al. · Nucl Med Biol 2026
- Multi-cohort screening of PANoptosis-related genes reveals PARP1 as a key target, and AZD5305 exerts anti-tumor effects in neuroblastoma.
Shi S, Zhang Z, Luo J, et al. · Front Oncol 2026
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.